Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.5.0.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Operating Activities:    
Net loss $ (10,596) $ (10,527)
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss on warrants [note 4 and note 5 [f]] (134) (35)
Depreciation 103 116
Stock-based compensation [note 5 [c] and note 5 [d]] 1,387 1,228
Changes in operating assets and liabilities:    
Interest receivable 64 37
Amounts receivable (293) 5,527
Prepaid expenses and other assets 714 842
Accounts payable (784) 230
Accrued liabilities other (19) (1,909)
Accrued clinical liabilities (2,263) (2,984)
Accrued compensation 61 (81)
Accrued litigation settlement [note 3, note 7 and note 8] 1,375  
Restricted cash   61
Excess lease liability   (194)
Lease obligation (16) 127
Deferred collaboration revenue [note 3] (5,040) 17,778
Net cash (used in) provided by operating activities (15,441) 10,216
Financing Activities:    
Proceeds from purchase agreement with Lincoln Park Capital, net of issuance costs   3,213
Taxes paid related to net share settlement of equity awards   (52)
Net cash (used in) provided by financing activities   3,161
Investing Activities:    
Purchase of investments (29,111) (2,025)
Proceeds from sale of investments   1,003
Proceeds from maturities of investments 20,858 8,012
Purchase of property and equipment (35) (265)
Net cash (used in) provided by investing activities (8,288) 6,725
Effect of exchange rate changes on cash   2
Net (decrease) increase in cash and cash equivalents (23,729) 20,104
Cash and cash equivalents at beginning of period 34,310 27,897
Cash and cash equivalents at end of period $ 10,581 48,001
Non cash financing activities    
Issued common stock in consideration for the purchase agreement with Lincoln Park Capital   $ 254